Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset
Introduction
To capitalise on innovations and continue to drive improvements, as part of the Reset, the NHS needs to understand how new patient pathways are performing and how covid-19 is impacting on its services regionally.
Data is key to achieving these goals and, in this article, we will explore how pharma can use it to help the NHS devise preventative, population-based solutions.
New pathways
The pandemic has brought big changes in the way that patients are managed, with more care being delivered in patients’ homes and fewer people accessing the NHS via traditional routes.
The NHS needs to be very data driven to map these developments and understand local populations and what they need. However, tracking patients and defining where they are in pathways is challenging.
There is a big role for pharma in helping the NHS track changes, from the new staff responsible for managing patients, to how this is being achieved and whether patient outcomes are improving as a result.
Hospital Episode Statistics (HES)
There are a number of different datasets that can help pharma to track patients. Hospital Episode Statistics (HES) data, which contains details of all admissions, outpatient appointments and A&E visits to NHS hospitals in England, is a good place to start.
Information available includes reasons for a hospital visit, treatments given, or procedures carried out, and whether admission was required. Pharma can also see how this data compares to previous years across different specialties to better understand how covid-19 has affected them.
Prescribing data
Prescribing data is key to understanding what is occurring more widely within the healthcare system based on the type of drugs that are being prescribed and where this is happening within the NHS.
The data can also provide useful insights on who is managing treatment. So, for instance, is it being managed by community prescribers in primary care rather than specialists?
Pharma can also use this data to find out where treatment is being administered, which is particularly insightful in terms of determining the number and type of patients requiring homecare services, and therefore homecare drugs. Prescribing data can also be used to identify who is monitoring the outcomes of drug regimens.
Impact of covid-19
In addition to tracking patients through specific pathways, it is vital to know about hospital capacity, particularly with regard to covid-19, as this will have a huge impact on the way care is managed regionally.
Key data that can be gathered includes patient flows and admission rates for covid-19 in different hospitals from the start of the pandemic through to the present time. This can be broken down to determine how covid-19 has impacted patients in a given therapy area, or subspecialty on a month by month basis, compared to previous years.
There is also much that industry can do to risk stratify patients during the pandemic and help the NHS develop new preventative strategies to manage them. For example, pharma can gather valuable insights into the potential complications and readmission risks faced by patients who have had coronavirus. This can help to form the basis for a range of preventative solutions with regard to products and how and where patients should be treated.
Planned care
Tackling the elective care backlog is a huge challenge and there is a role for pharma in helping the NHS manage patients while they wait for surgery or other treatment. Industry can also monitor hospital capacity to determine where patients could be brought back into the system.
In terms of patient management, industry could, for example, identify and risk stratify patients who are highly likely to develop further complications while waiting for treatment and devise ways to safely manage them in the most appropriate setting.
So, a company specialising in pain management, for instance, could risk stratify older people facing long waits for hip or knee replacements, who may need extended, different and perhaps more intense pain management regimens, and devise appropriate treatment plans.
Conversely, by tracking covid-related activity within hospitals, pharma could find out if the number of patients accessing certain services has decreased and whether there is capacity to resume them.
Conclusion
The NHS must capitalise on the positive changes that have been made in service design and delivery as a result of the pandemic and continue to innovate if it is to tackle the challenges posed by covid-19. However, it needs a wealth of population-based data to inform its decision-making.
There is a key role for pharma to play here in using data and information to help the NHS track patients through new pathways, understand where they are working well and how improvements can be made. There is also much that industry can do to help the NHS monitor the impact of covid-19 on a regional basis and risk stratify patients who are being impacted by it.
Ends
Oli Hudson is Content Director at Wilmington Healthcare. For information on Wilmington Healthcare, visit www.wilmingtonhealthcare.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Considering a portfolio review?
Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...
UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW
Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...
MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...
ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS
With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...
HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...
ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed
Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...
EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES
As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...
UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS
Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...